ELOXX PHARMACEUTICALS, INC. (ELOX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 16.97M USD | Liabilities, Current |
| Cash and equivalents | 61.96M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $16.97M | $61.96M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $16.09M | $6.36M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $17.18M | $4.79M | (m) | (m) | (m) | (m) |
| 2025-12-12 | (m) | (m) | $4.80M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $572.00K | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $450.00K | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $27.31M | $111.00K | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $22.70M | $1.13M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $23.47M | $4.78M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $21.25M | $4.33M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $19.46M | $4.90M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $23.09M | $19.21M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $21.68M | $24.55M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $19.50M | $30.05M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $19.17M | $39.77M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $9.96M | $42.27M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $9.51M | $52.43M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $15.21M | $56.73M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $12.69M | $18.25M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $9.84M | $24.67M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $9.98M | $30.59M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $10.77M | $30.35M | $6.77M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $11.08M | $25.88M | $18.08M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $11.81M | $22.49M | $33.78M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $11.23M | $22.16M | $42.78M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $10.99M | $49.33M | $26.97M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $8.42M | $44.58M | $8.93M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $7.81M | $48.61M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $5.08M | $55.34M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $4.36M | $63.41M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $5.65M | $18.29M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $3.42M | $24.05M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $1.08M | $957.87K | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $2.77M | $33.20K | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $1.06M | $241.95K | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $764.20K | $149.19K | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $467.27K | $287.06K | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $368.99K | $810.81K | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $377.35K | $1.53M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $569.15K | $2.37M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $675.49K | $3.35M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $778.52K | $3.33M | (m) | $0.00 | (m) | (m) |
| 2015-03-31 | (m) | $1.66M | $469.98K | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $2.55M | $2.11M | (m) | $203.91K | (m) | (m) |
| 2014-09-30 | (m) | $1.69M | $3.84M | (m) | $43.13K | (m) | (m) |
| 2014-06-30 | (m) | $1.83M | $6.11M | (m) | $43.13K | (m) | (m) |
| 2014-03-31 | (m) | $1.06M | $6.20M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $3.28M | $6.12M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $3.60M | $789.18K | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $3.21M | $1.60M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $3.22M | $1.58M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $3.75M | $640.13K | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $3.44M | $1.31M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $3.16M | $2.00M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $3.53M | $3.21M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $3.45M | $1.55M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $3.80M | $2.84M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $3.27M | $3.61M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $4.86M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $4.84M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $6.29M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $8.03M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $380.57K | (m) | (m) | (m) | (m) |
| 1998-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |